Dr Laura Rosa Brunet | Chief Scientific Officer
Immodulon Therapeutics Ltd

Dr Laura Rosa Brunet, Chief Scientific Officer, Immodulon Therapeutics Ltd

Laura has 15 years of experience in the pharmaceutical industry, having joined the field after being awarded research fellowships at Cornell University (Ithaca, NY, USA) and the University of Cambridge (Cambridge, UK). She obtained her doctorate from Harvard University (Boston, MA, USA). With a strong background in immunology, she has substantial scientific experience in infectious diseases, allergic inflammation and oncology, and has had over 45 peer-reviewed papers published in leading journals. After leaving academia, Laura worked for a small biotech company, Stanford Rook Ltd (London, UK), progressing a lead mycobacterial product from preclinical research to clinical trials. As a scientific consultant she has been involved in a number of projects for large pharma and international agencies, addressing manufacturing, clinical development and policy position statements. Laura joined Immodulon in 2009 as Chief Scientific Officer and is responsible for research and development, delivering preclinical and clinical research programmes in line with business strategy and IP activities.


Day 3 Oct 12th Immune Profiling @ 11:20

Harnessing natural bacterial products to develop pioneering and gentle immunotherapy treatments

  • The potential to develop drugs from bugs
  • The Old Friend’s hypothesis: implications for the field of immunotherapy
  • Overview of current clinical and pre-clinical development programmes
  • Highlighting immune-modulatory mode of mechanism

back to speakers